Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 known ✓ | Q07820 | 1/20 | 0.39 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.39 |
| ▸ | BCR known ✓ | P11274 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.48 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.42 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL8445673 | 0.92 | TRIM24 (0.52) | TRIM24TRIM33LMNAMAPTNFKB1 | |
| Formaldehyde SCHEMBL28020903 | 0.85 | TRIM24 (0.58) | TRIM24TRIM33LMNAMAPTNFKB1 | |
| Ethane SCHEMBL2943462 | 0.85 | TRIM24 (0.52) | TRIM24TRIM33LMNAMAPTNFKB1 | |
| SCHEMBL20076 | 0.85 | — | — | |
| SCHEMBL29511549 | 0.85 | — | — | |
| Benzene SCHEMBL23581564 | 0.83 | TRIM24 (0.54) | TRIM24TRIM33LMNAMAPTNFKB1 | |
| Methane SCHEMBL2951846 | 0.83 | TRIM24 (0.54) | TRIM24TRIM33LMNAMAPTNFKB1 | |
| Bromide SCHEMBL2361069 | 0.83 | TRIM24 (0.54) | TRIM24TRIM33LMNAMAPTNFKB1 | |
| Fluoride SCHEMBL2197395 | 0.83 | TRIM24 (0.54) | TRIM24TRIM33LMNAMAPTNFKB1 | |
| SCHEMBL6122881 | 0.83 | TRIM24 (0.54) | TRIM24TRIM33LMNAMAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207343-B2 | Process for preparing montelukast and salts thereof | LAURUS LABS PRIVATE LIMITED (IN) | 2012-06-26 | — | — | US | claimed |
| US-20110112300-A1 | IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | Aptuit Laurus Pvt. Ltd. (IN) | 2011-05-12 | — | — | US | claimed |
| EP-2288595-A2 | AN IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | Aptuit Laurus Pvt Limited (IN) | 2011-03-02 | — | — | EP | claimed |
| WO-2009144742-A2 | AN IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | APTUIT LAURUS PVT LIMITED (IN) | 2009-12-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112300-A1 | IMPROVED PROCESS FOR PREPARING MONTELUKAST AND SALTS THEREOF | MPST, TST, CMA1 | MCL1 2802/4885ABL1 1128/4885BCR 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.